Effect of 5-(phenylselenenyl)acyclouridine, an inhibitor of uridine phosphorylase, on plasma concentration of uridine released from 2', 3', 5'-tri-O-acetyluridine, a prodrug of uridine: Relevance to uridine rescue in chemotherapy

Cancer Chemotherapy and Pharmacology

Volumn 46, Issue 3, 2000, Pages 235-240

  Ashour, Osama M ^a   Naguib, Fardos N M ^a   Goudgaon, Naganna M ^b,c   Schinazi, Raymond F ^b,c   El Kouni, Mahmoud H ^a  

^a UNIVERSITY OF ALABAMA AT BIRMINGHAM   (United States)

^b ATLANTA VA MEDICAL CENTER   (United States)

^c EMORY UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

5 (Phenylselenenyl)acyclouridine; Chemotherapy; Inhibitor; Triacetyluridine; Uridine phosphorylase

Indexed keywords

2',3',5' TRI O ACETYLURIDINE; 5 (PHENYLSELENYL)ACYCLOURIDINE; ACYCLOURIDINE DERIVATIVE; ENZYME INHIBITOR; UNCLASSIFIED DRUG; URIDINE DERIVATIVE; URIDINE PHOSPHORYLASE;

ANIMAL EXPERIMENT; AREA UNDER THE CURVE; ARTICLE; CANCER CHEMOTHERAPY; CONTROLLED STUDY; DRUG BIOAVAILABILITY; DRUG BLOOD LEVEL; DRUG EFFECT; FEMALE; MALIGNANT NEOPLASTIC DISEASE; MOUSE; NONHUMAN; PRIORITY JOURNAL;

ANIMALS; BIOLOGICAL AVAILABILITY; DRUG SYNERGISM; ENZYME INHIBITORS; FEMALE; MICE; ORGANOSELENIUM COMPOUNDS; PRODRUGS; URACIL; URIDINE; URIDINE PHOSPHORYLASE;

EID: 0033802299     PISSN: 03445704     EISSN: None     Source Type: Journal    
DOI: 10.1007/s002800000138     Document Type: Article

References (44)

1. 5-(m-Benzyloxybenzyl)barbituric acid acyclonucleoside, a uridine phosphorylase inhibitor and 2', 3', 5'-tri-o-acetyluridine, a prodrug of uridine as modulators of plasma uridine concentration, Implication for chemotherapy
2. Modulation of plasma uridine concentration by 5-(phenylselenenyl)acyclouridine an inhibitor of uridine phosphorylase: Relevance to chemotherapy
3. Uridine pharmacokinetics in cancer patients
4. Uridine-induced hyperthermia in the rabbit
5. In-vivo-Untersuchungen zur Metabolisierung der Pyrimidinnucleoside
6. Tissue-specific enhancement of uridine utilization and 5-fluorouracil therapy in mice by benzylacyclouridine
7. Enhancement of fluorouracil therapy by the manipulation of tissue uridine pools
8. Tissue-specific expansion of uridine pools in mice. Effects of benzylacyclouridine, dipyridamole and exogenous uridine
9. Species-dependent differences in the biochemical effects and metabolism of 5-benzylacyclouridine
10. Circadian rhythm of hepatic uridine phosphorylase activity and plasma concentration of uridine in mice
11. Differential Effect of benzylacyclouridine on the toxic and therapeutic effects of azidothymidine in mice
12. Novel single-pass exchange of circulating uridine in rat liver
13. Interactive graphic package for pharmacokinetic analysis
14. Phenylselenenyl and phenylthio substituted pyrimidines as potential inhibitors of dihydrouracil dehydrogenase and uridine phosphorylase
15. Uridine catabolism in Kupffer cells, endothelial cells, and hepatocytes
16. Effect of 5-diazouracil on the catabolism of circulating pyrimidines in rat liver and kidneys
17. Uridine catabolism by the isolated perfused rat liver
18. Phase I trial of PN401, an oral prodrug of uridine, to prevent toxicity from fluorouracil in patients with avoidance responding
19. Anti-human immunodeficiency virus type 1 therapy and peripheral neuropathy: Prevention of 2', 3'-dideoxycytidine toxicity in PC12 cells, a neuronal model by uridine and pyruvate
20. Use of uridine rescue to enhance the antitumor selectivity of 5-fluorouracil
21. Uridine rescue from the lethal toxicity of 5-fluorouracil in mice
22. Comparison of the bioavailability of uridine in mice after either oral or parenteral administration
23. Phase I and pharmacokinetic studies of high-dose uridine intended for rescue from 5-fluorouracil toxicity
24. An algorithm for least squares estimation of nonlinear parameters
25. High-dose 5-fluorouracil with delayed uridine 'rescue' in mice
26. Use of oral uridine as a substitute for parenteral uridine rescue of 5-fluorouracil therapy, with and without the uridine phosphorylase inhibitor 5-benzylacyclouridine
27. Uridine regulation by the isolated rat liver: Perfusion with an artificial oxygen carrier
28. Effect of 5-benzylacyclouridine, a potent inhibitor of uridine phosphorylase, on the metabolism of circulating uridine by the isolated rat liver
29. Salvage of circulating pyrimidine nucleosides in the rat
30. Enzymes of uracil catabolism in normal and neoplastic human tissues
31. Circadian rhythm of orotate phosphoribosyltransferase, pyrimidine nucleoside phosphorylases and dihydrouracil dehydrogenase in mouse liver: Possible relevance to chemotherapy with 5-fluoropyrimidines
32. Clinical relevance of biochemical modulation of 5-fluorouracil
33. Effect of pyrimidine nucleosides on body temperatures of man and rabbit in relation to pharmacokinetic data
34. Uridine-induced hypothermia in mice and rats in relation to plasma and tissue levels of uridine and its metabolites
35. In vitro biochemical and in vivo biological studies of the uridine 'rescue' of 5-fluorouracil
36. Phase I clinical and pharmacological studies of benzylacyclouridine, a uridine phosphorylase inhibitor
37. Uridine allows dose escalation of 5-fluorouracil when given with N-phosphoacetyl-1-aspartate, methotrexate, and leucovorin
38. Uridine reverses the toxicity of 3'-azido-3'-deoxythymidine in normal human granulocyte-macrophage progenitor cells in vitro without impairment of antiretroviral activity
39. Novel pharmacologic approaches for the treatment of AIDS and potential use of uridine phosphorylase inhibitors
40. Effects of 5-benzylacyclouridine, an inhibitor of uridine phosphorylase, on the pharmacokinetics of uridine in rhesus monkeys: Implications for chemotherapy
41. Clinical and pharmacokinetic studies of prolonged administration of high-dose uridine intended for rescue from 5-FU toxicity
42. Reversal of 5-fluorouracil induced myelosuppression by prolonged administration of high-dose uridine
43. Clinical and pharmacologic study of orally administration uridine
44. Modulation of fluorouracil toxicity with uridine